GFI APAC report says China's biomanufacturing drive could reshape microbial protein production

China is rapidly emerging as a global manufacturing powerhouse for microbial proteins, with its expanding fermentation capacity, government backing and lower production costs creating opportunities that international companies may find increasingly difficult to ignore, according to a new report from GFI APAC.

• GFI APAC reported that China's fermentation capacity, lower manufacturing costs and policy support are accelerating microbial protein production and attracting international partnerships.
• The report said established fermentation companies and emerging startups are investing in large-scale facilities, with several projects targeting annual capacities of 20,000 tonnes or more.
• GFI APAC concluded companies should weigh geopolitical and intellectual property risks against the potential cost of remaining outside China's expanding biomanufacturing ecosystem.

The report, China's Biomanufacturing Boom: Opportunities and Risks for Microbial Protein Producers, argues that while geopolitical tensions, tariffs and intellectual property concerns remain genuine risks, companies that choose not to engage with China's fast-growing biomanufacturing ecosystem could ultimately find themselves at a competitive disadvantage.

China's industrial fermentation sector is already among the world's largest, supported by decades of investment in producing vitamins, amino acids and pharmaceutical ingredients. As margins in many of those mature markets have come under pressure from oversupply and increased competition, manufacturers are increasingly turning their attention to higher-value applications such as microbial proteins and precision fermentation.

According to the report, this shift is being reinforced by national policy that places biomanufacturing and food security among China's long-term strategic priorities. The combination is encouraging both established fermentation companies and emerging startups to invest heavily in novel food production.

The report highlights a series of large-scale projects already underway. Companies including Fushine Biotech, Angel Yeast and More Meat are building or expanding production facilities capable of producing between 20,000 and 30,000 tonnes annually. Established fermentation manufacturers are also partnering with alternative protein companies to commercialize new ingredients, while investing in capabilities such as strain development and process optimization.

GFI APAC said China now offers manufacturing support throughout the scale-up journey, from pilot production to full commercial manufacturing, making it an increasingly attractive destination for overseas companies seeking to reduce costs and accelerate commercialization.

Rather than relying solely on government subsidies, the report argues that China's competitive advantage stems from extensive experience constructing fermentation facilities, integrated supply chains, streamlined decision-making, lower construction costs and supportive industrial policy.

It also points to China's growing scientific capabilities. While many manufacturers built their businesses supplying mature fermentation products, companies are increasing research and development spending while expanding scientific teams to move into higher-value biomanufacturing applications.

Alongside established players, a new generation of domestic startups is emerging across areas including mycoprotein, cultivated meat, human milk proteins and fermentation-derived ingredients. Many are combining proprietary research with access to large-scale manufacturing infrastructure through partnerships with established industrial companies.

Government support extends beyond manufacturing, according to the report. China has increasingly incorporated alternative proteins and synthetic biology into national food security and industrial policy, while regulatory pathways for ingredients produced using genetically modified microorganisms have become more clearly defined.

Preparatory documents for China's forthcoming biomanufacturing Five-Year Plan also suggest biomanufactured foods and microbial proteins will play an important role in future industrial development.

Despite these advantages, GFI APAC cautions that manufacturing in China presents several trade-offs. The report identifies geopolitical tensions, tariffs and export restrictions among the biggest uncertainties facing overseas companies, while noting that some investors, particularly in the US, remain reluctant to back businesses that rely on Chinese production. It also recommends companies carefully structure manufacturing partnerships to protect intellectual property and clearly define ownership of strains, processes and improvements developed during commercialization.

Rather than advocating a single approach, the report outlines several partnership models, from contract manufacturing to co-development agreements and joint ventures, depending on where a company's competitive advantage lies and how much manufacturing support it requires.

The report concludes that the biggest strategic question may not be whether engaging with China carries risks, but whether companies can afford to ignore a manufacturing ecosystem that is rapidly expanding in scale, capability and cost competitiveness.

If you liked this, check these out...

• Biosphere bolsters biomanufacturing ambitions with NovoNutrients acquisition

• Curve and Digital Tvilling build AI biomanufacturing platform to lower precision fermentation costs

• Cellcraft launches AI operating system for bioreactors to address control gap in biomanufacturing